bempedoic acid/ezetimibe vs fenofibrate
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of bempedoic acid/ezetimibe and fenofibrate. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Fibrates Clinical Impact: Both fenofibrate and ezetimibe (a component of NEXLIZET) may increase cholesterol excretion into the bile, leading to cholelithiasis. Coadministration of NEXLIZET with fibrates other than fenofibrate is not recommended [see Adverse Reactions (6.1) ] . Intervention: If cholelithiasis is suspected in a patient receiving NEXLIZET and fenofibrate, gallbladder studies are indicated and alternative lipid-lowering therapy should be considered.
Nexlizet
TriCor, Antara
Nexlizet is a combination medicine that helps lower cholesterol. It is used with diet and exercise to lower LDL-C (bad cholesterol) in adults.
Fenofibrate is a medicine that helps lower bad cholesterol and fats (triglycerides) in your blood, while raising good cholesterol.
Nexlizet is used to lower LDL-C (bad cholesterol) in adults who have high cholesterol. This includes people with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). One of the medicines in Nexlizet can also lower the risk of heart problems like heart attack and stroke in adults who are at high risk and cannot take statins.
This medicine is used with a diet to treat high cholesterol and high levels of triglycerides (fats) in the blood. It helps adults who have primary hypercholesterolemia or mixed dyslipidemia. It can also treat adults with severe hypertriglyceridemia. However, fenofibrate has not been proven to prevent heart disease in people with type 2 diabetes.
Nexlizet contains two medicines that work in different ways to lower cholesterol. Bempedoic acid blocks an enzyme in your liver that makes cholesterol. Ezetimibe stops your body from absorbing cholesterol from food.
Fenofibrate is a type of drug called a PPAR alpha agonist. It works by activating a protein in your body that helps break down fats and cholesterol. This leads to lower levels of bad cholesterol and triglycerides, and higher levels of good cholesterol.
- • Upper respiratory tract infection (like a cold)
- • Muscle spasms
- • High uric acid levels in the blood
- • Back pain
- • Stomach pain or discomfort
- • Abnormal liver function tests
- • Increased ALT (a liver enzyme)
- • Increased AST (a liver enzyme)
- • Increased CPK (a muscle enzyme)
- • Runny nose
- Muscle pain 53
- Joint pain 51
- Pain in your arms or legs 40
- Muscle spasms 32
- Tiredness 30
- Nausea 2,912
- Fatigue 2,840
- Diarrhoea 2,681
- Dyspnoea 2,099
- Headache 2,058
This medicine can raise uric acid levels in your blood, which can cause gout. Tell your doctor if you have symptoms of high uric acid, like joint pain or swelling. Nexlizet can also increase your risk of tendon rupture. Stop taking Nexlizet and call your doctor right away if you have tendon pain, swelling, or difficulty moving.
Fenofibrate can cause liver problems. Your doctor should check your liver function with blood tests before you start taking it and regularly while you are taking it. Stop taking fenofibrate and tell your doctor right away if you have signs of liver problems, such as yellowing of your skin or eyes, dark urine, or stomach pain. Fenofibrate can also cause muscle pain or weakness, especially if you are also taking a statin medicine. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness.
This medicine may harm your unborn baby. Do not take Nexlizet if you are pregnant or planning to become pregnant. Talk to your doctor about other ways to lower your cholesterol during pregnancy.
It is not known if fenofibrate will harm an unborn baby. You should only use fenofibrate during pregnancy if your doctor decides that the benefit outweighs the risk. You should not breastfeed while taking fenofibrate.
Also Compare, Nearby Drugs
Compare fenofibrate with
How to Read This bempedoic acid/ezetimibe vs fenofibrate Comparison
bempedoic acid/ezetimibe is classified in the ACL Inhibitor / Cholesterol Absorption Inhibitor drug class, while fenofibrate sits within the Fibrate class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, bempedoic acid/ezetimibe has 206 submissions while fenofibrate has 12,590. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to both of these medicines can increase the amount of cholesterol that moves into the bile, which may cause gallstones to form.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for bempedoic acid/ezetimibe or fenofibrate.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.